The collective evidence therefore suggest that SPATA2 over-expression is associated with a non-T-cell-inflamed TME in CRC, and that SPATA2 might mediate T cell exclusion by inhibiting the production of CXCL9, CXCL10, and CXCL11 from tumor cells. Here, CXCL10 is linked to neoplasm.